CSCIF — COSCIENS Biopharma Inc.
—
OTC ·
Materials ·
Chemicals ·
CIK 1113423 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,143,000 | 1,737,000 | 422,000 | -202,000 | 18,851,000 | 5,278,000 | 4,009,000 |
| Mar 2026 | 1,888,000 | 793,000 | -730,000 | 10,757,000 | 18,841,000 | 5,005,000 | 3,522,000 |
| Dec 2025 | 1,766,000 | 609,000 | -2,388,000 | -2,183,000 | 21,431,000 | 7,307,000 | 17,589,000 |
| Sep 2025 | 1,483,000 | 621,000 | -2,007,000 | -1,819,000 | 23,859,000 | 8,524,000 | 18,779,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,770,000
Investing CF
$134,000
Financing CF
$-289,000
CapEx
$-712,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.96
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-9,751,000
Inventory
$1,099,000
Receivables
$1,994,000
ST Investments
—
EBIT TTM
$-6,731,000
Pretax Income TTM
$-6,875,000
Interest Exp TTM
$144,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,725,000
EBITDA
$-5,214,000
Free Cash Flow
$-3,287,625
Enterprise Value
$2,154,181
Total Cash
$5,278,000
Total Debt
$1,956,000
Shares Out
996,166
Trailing EPS
$-5.47
Book Value
$13.98
ROE
-52.8%
ROA
-16.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,498,000 | -10,365,000 | -10,358,000 | 21,431,000 | 17,589,000 | 3,842,000 | -8,473,000 |
| Dec 2024 | 9,587,000 | -14,023,000 | -15,309,000 | 35,070,000 | 21,909,000 | 13,161,000 | -14,568,000 |
| Dec 2023 | 7,143,000 | -4,629,000 | -3,485,000 | 23,745,000 | 2,710,000 | 21,035,000 | -2,582,000 |
| Dec 2022 | 14,572,000 | 4,320,000 | 3,448,000 | 27,803,176 | 4,012,218 | 23,790,959 | 5,229,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PG | PROCTER & GAMBLE Co | $336.58B | $144.91 | — |
| LIN | LINDE PLC | $221.03B | $479.48 | — |
| UL | UNILEVER PLC | $128.55B | $59.70 | — |
| ECL | ECOLAB INC. | $76.73B | $273.70 | — |
| CL | COLGATE PALMOLIVE CO | $67.17B | $84.26 | — |
News headlines (Yahoo Finance, 1h cache)
COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
2026-09-16 22:00 · Yahoo
COSCIENS ACQUIRES NUALTIS CORP.
2026-09-10 20:15 · Yahoo
COSCIENS Biopharma Inc. Reports Q2 2026 Results
2026-08-11 21:30 · Yahoo
COSCIENS Biopharma Inc. Completes Share Capital Amendment
2026-07-03 12:30 · Yahoo
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
2026-06-18 12:30 · Yahoo
COSCIENS Biopharma Inc. Reports Q1 2026 Results
2026-05-12 21:05 · Yahoo
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
2026-04-20 12:00 · Yahoo
COSCIENS Biopharma Acquires Pharma Tech Business Nualtis For $15 Million Cash
2026-09-10 20:43 · Yahoo
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
2025-12-01 22:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.